Beyond pharmaceuticals: TTY seeks to raise quality of life through science and technology
From a conventional generic drug manufacturer in 1960, TTY gradually distinguished itself as a biotech pharmaceutical company, and in the past decade, it has grown to specialise in oncology and anti-infection
Complex, delicate and utterly difficult, cancer remains a major cause of death even after more than four decades of intensified research and an all-out war waged by the medical industry. Technological barriers are as high as ever, but better and more accessible treatments are steadily gaining ground – thanks to innovators such as TTY Biopharm, which have been on the frontline in developing equally complex and difficult breakthroughs.
“Cancer is not faceless. Every person battling cancer or an infectious disease has an entire family suffering along with them,” says TTY vice-chairman Gary Tseng. “That is why our vision is not to merely develop formulations, but to raise the quality of life for mankind through science and technology.”
Under its TTY Oncology Translational Research Center, the Taipei-based company develops new medical entities, including innovative therapeutic modalities in areas of unmet medical needs. It offers contract research, development and manufacturing services, focusing on speciality products encapsulated in liposomes and microspheres for targeted and efficient delivery. TTY also develops conventional products including immediate-release and sustained-release drugs, liquid injection forms, gels and ointments.
From a conventional generic drug manufacturer in 1960, TTY gradually distinguished itself as a biotech pharmaceutical company. Backed by a government that supported the rise of a research-and-development-oriented pharmaceutical industry in the past decade, it grew to specialise in oncology and anti-infection – and began to build a global network.
Cancer is not faceless. Every person battling cancer or an infectious disease has an entire family suffering along with them
One of the first few pharmaceutical companies to enter the mainland China market in the 1980s, TTY established two major subsidiaries on the mainland conducting mainly R&D. To accelerate clinical trials and the launch of products in the pipeline, the company welcomes joint ventures with potential long-term partners who have local expertise and connection with the China Food and Drug Administration.
“Most importantly, our partners must share our dream of raising the quality of life,” Tseng says. “Integration among different countries is key, particularly in developing bio drugs, which entail massive race-based data collection and in-depth analyses.”
TTY also has dealer distribution networks in more than 50 countries, and subsidiaries in Vietnam, the Philippines and Thailand. Through these markets, the company aims to gain support initially in Southeast Asia for the next few years, and then create broader traction as it undertakes bigger projects worldwide.
“Beyond contributing research and breakthroughs, we hope to help consumers make informed decisions, challenge peers to create better products, and pave the way for improved drug regulations across the industry and around the globe,” Tseng says.
http://www.tty.com.tw
